*Purpose: Aspergillus infection is the most common mold infection in solid organ transplant recipients and its consequences can be fatal. Data in intestinal transplants (ITx) recipients is scarce. In this study, we compare the clinical characteristics and outcomes of ITx recipients with and without invasive aspergillosis (IA) at a large transplant center.

*Methods: Single-center, retrospective cohort-study of ITx performed between January 2009 to October 2019. The patients were followed until October 2020. We determined the incidence of IA in our cohort. We assessed if there were any differences in demographics, type of ITx, IA risk factors (ICU stay prior to ITx, retransplantation, reoperation within 1 month of ITx), and one-year mortality and proven-biopsy rejection between those ITx recipients with and without IA. In addition, we evaluated for risk factors, treatments and outcomes for those who were diagnosed with IA.

*Results: Seventy-eight adult patients underwent ITx. Seven were excluded due to peri-transplant mortality. Therefore, 71 patients were included. The incidence of IA in our cohort was 8.5 per 100 transplanted patients. There were no differences in demographics, IA risk factors and one-year mortality and rejection between both groups (Table 1). Most of the IA cases were pulmonary, occurred within 6 months of ITx and were treated with voriconazole. The IA was cured in four (66.7%) of the patients (Table 2).

*Conclusions: Our ITx cohort demonstrated a high incidence of IA. Larger studies are needed to determine the risk factors associated with IA in this transplant population.

« Back to 2021 American Transplant Congress